Microencapsulation for Human Islet Transplantation
Encapsulation of islets is a promising strategy to deliver a cell therapy for treatment of type 1 diabetes without the need for anti-rejection drugs. The most common form of encapsulation is the microcapsule, which is made from sodium alginate, and is made robust by brief exposure to either Ca2+ or Ba2+. Transplantation of encapsulated human islets into diabetic immunodeficient mice results in rapid normalization of blood glucose levels. The number of encapsulated islets required to achieve normoglycemia is the same as the number of non-encapsulated islets. The minimal islet mass is 2000-3000 islet equivalents (IEQ), but this number can be reduced to 750-1000 IEQ if the encapsulated islets are pretreated overnight with 100µM desferrioxamine prior to transplantation. Transplantation of encapsulated islets into recipients with type 1 diabetes has been performed by several groups, with long term function of the grafts and a reduction of insulin requirements, but not insulin-independence, being demonstrated. A major issue that needs to be addressed to improve efficacy, is the prevention of pericapsular fibrotic overgrowth. This can lead to islet necrosis, as the pores that permit passage of nutrients and oxygen are obstructed. This overgrowth is caused by an inflammatory response to the encapsulation material and/or to antigens that leak through the pores. The peritoneal cavity seems not to be the best site for implantation, because of the large number of macrophages. Better survival is achieved in animals when encapsulated cells are grafted subcutaneously, but the low oxygen levels here limit the function of β cells since they thrive best at higher oxygen levels. An alternative to using microcapsules is the macrocapsule, but as yet there have been no human studies with islets examining its benefits. Reasons for continuing to pursue the use of encapsulated islets in the clinic are twofold. Firstly, they offer a potential means of overcoming the need for subcutaneous insulin administration without the need for anti-rejection drugs. Secondly, they lay the foundation for other forms of encapsulated allogeneic cell therapies, namely with stem cells or cells derived from them.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: August 1, 2013
More about this publication?
- Micro and Nanosystems publish significant original work, topical reviews and guest edited issues ranging from technologies and systems to product innovation and new manufacturing processes with features at the micro and nanoscale. Applications for micro and nanosystems in areas such as health, environmental, food, security and consumer goods will be covered. The topics to be addressed will include Lab-on-a-chip, microfluidics, nano-biotechnology, micro and nanomanufacturing, printed electronics and MEMS.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites